| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% | ![]() |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20594 | JTE-151 | 1404380-58-0 | ≧98.0% | ![]() |
| JTE-151 是一种 RORγ 抑制剂,可通过抑制与 Th17 细胞活化相关的 ROR | ||||
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | ![]() |
| QN-302 是一种 G4选择性转录抑制剂。 | ||||
| 20640 | AAG-1 ( FLAG-003 ) | 1614235-14-1 | ≧98.0% | ![]() |
| FLAG-003 是一种多效水溶性小分子治疗药物,旨在通过两种成熟的作 | ||||
| 20641 | KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) | 2082765-42-0 | ≧98.0% | ![]() |
| KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) 是一种蛋白质精氨酸脱亚胺酶的 | ||||
| 20642 | OATD-02 | 2146132-73-0 | ≧98.0% | ![]() |
| OATD-02 是一种口服双精氨酸酶抑制剂(ARG1 和 ARG2),目前在 Molecu | ||||
| 20650 | Sonrotoclax (BGB-11417) | 2383086-06-2 | ≧98.0% | ![]() |
| Sonrotoclax is an antineoplastic. | ||||
| 262401 | MRTX1719 | 2630904-45-7 | ≧96.0% | |
| MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively | ||||
| 24004 | T-1095 | 209746-59-8 | ≧96.0% | ![]() |
| T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). | ||||
| 24008 | RNK-05047 | 2503036-46-0 | ≧98.0% | ![]() |
| RNK-05047 为BRD4降解剂,其在小鼠荷瘤异种移植模型中展现出显著抑 | ||||
| 24010 | Zasocitinib | 2272904-53-5 | ≧98.0% | ![]() |
| Zasocitinib是一种作用于非受体酪氨酸蛋白激酶 (TYK2)靶点的抑制 | ||||
| 24011 | Zongertinib ( BI 1810631 ) | 2728667-27-2 | ≧98.0% | ![]() |
| Zongertinib [BI 1810631] 是一种人表皮生长因子受体 2 (HER2) 抑制剂。 | ||||
